Key Highlights
•
In a large real-world study, people with relapsing-remitting multiple sclerosis who took natalizumab had fewer relapses each year and a higher chance of disability improvement compared to those taking anti-CD20 therapies like ocrelizumab or rituximab.
Source →
•
Natalizumab also caused fewer side effects overall than anti-CD20 therapies, though patients were less likely to stay on it long-term, giving doctors valuable information for choosing the best treatment for each patient.
Source →
•
A large study using UK Biobank data found that a traumatic brain injury more than doubles a person’s risk of developing dementia before age 65, and the risk is even higher for moderate or severe head injuries.
Source →
•
The link between head injury and dementia was stronger for early-onset dementia (occurring before age 65) than for dementia that appears later in life, highlighting the importance of preventing head injuries to protect long-term brain health.
Source →
•
Scientists discovered that a protein called GPR84, found on immune cells, is a key driver of the inflammation that causes the severe skin ulcers seen in Buruli ulcer, a neglected tropical disease.
Source →
•
Blocking the GPR84 receptor in lab models reduced tissue damage, suggesting a potential new way to treat this disfiguring infection that currently relies on long courses of antibiotics.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
